A combination of rebaudioside A and neohesperidin dihydrochalcone suppressed weight gain by regulating visceral fat and hepatic lipid metabolism in ob/ob mice

Authors: KIM, YERI - Ewha Woman'S University; HAN, HYEJIN - Ewha Woman'S University; OH, YEONSOO - Ewha Woman'S University; SHIN, HAKDONG - Sejong University; PARK, GWONCHEOL - Sejong University; PARK, SUNGHEE - Chungbuk National University College Of Medicine; MANTHEY, JOHN - Retired ARS Employee; KIM, YANG - Seoul National University; KIM, YURI - Ewha Woman'S University

Submitted to: Food Science and Biotechnology
Publication Type: Peer Reviewed Journal
Publication Acceptance Date: 7/13/2023
Publication Date: 8/26/2023
Citation: Kim, Y., Han, H., Oh, Y., Shin, H., Park, G., Park, S., Manthey, J.A., Kim, Y., Kim, Y. 2023. A combination of rebaudioside A and neohesperidin dihydrochalcone suppressed weight gain by regulating visceral fat and hepatic lipid metabolism in ob/ob mice. Food Science and Biotechnology. https://doi.org/10.1007/s10068-023-01391-1.
DOI: https://doi.org/10.1007/s10068-023-01391-1

Interpretive Summary: Two synthetic compounds, rebaudioside A (Reb A) and neohesperidin dihydrochalcone (NHDC) are known as intense sweeteners. This study aimed to examine the anti-obesity effects of Reb A and NHDC in mice. When these compounds were used together, there were decreases in body weight gain, food efficiency ratio, and fat mass. In addition, mice that received these two compounds together showed increased populations of beneficial gut bacteria. These results suggest that supplementation with Reb A and NHDC may be an effective treatment for obesity-related metabolic disorders.

Technical Abstract: Rebaudioside A (Reb A) and neohesperidin dihydrochalcone (NHDC) are known as intense sweeteners. This study aimed to examine the anti-obesity effects of Reb A and NHDC. C57BL/6 J-ob/ob mice were supplemented with Reb A (50 mg/kg body weight [b.w.]), NHDC (100 mg/kg b.w.), or their combination (COMB) for 4 weeks. COMB-supplemented mice showed significant reduction in b.w. gain, food efficiency ratio, and fat mass. Additionally, mice in the COMB group showed suppressed levels of genes related to adipogenesis, lipogenesis, and lipolysis in the perirenal fat and the levels of hepatic triglyceride, glutamic oxaloacetic transaminase, and glutamic pyruvic transaminase. The lipogenesis and pro- inflammatory gene expressions were also downregulated in the liver, whereas ß-oxidation related genes were upregulated in the COMB group. In addition, mice that received COMB showed distinct gut microbiota structure, enriched in Blautia and Parabacteroides, and depleted in Faecalibaculum and Mucispirillum, in relation to the control group. These results suggest that supplementation with Reb A and NHDC may be an effective treatment for obesity-related metabolic disorders.